The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.
Menactra was first approved by the FDA in January 2005 for people ages 11 to 55. The vaccine Menomune was previously the only meningococcal vaccine available in the United States for use in children ages 2 and older, the FDA said Thursday in a release.
Both products are manufactured by Sanofi Pasteur Inc. of Swiftwater, Pa.
Meningitis, a serious inflammation of the lining that surrounds the spinal cord and brain, can cause death or permanent brain injury.
Copyright 2007 by United Press International
Related stories:
FDA considers expanded use of HPV vaccine
Pharmaceutical manufacturer Merck & Co. Inc. said the U.S. Food and Drug Administration will consider expanding the use of its cervical cancer vaccine.
FDA expands meningitis vaccine age range
The U.S. Food and Drug Administration has expanded the approved age range for Menactra, a bacterial meningitis vaccine.
Study: No link between measles vaccine and autism
(AP) -- New research further debunks any link between measles vaccine and autism, work that comes as the nation is experiencing a surge in measles cases fueled by children left unvaccinated.
Cervical cancer prevention should focus on vaccinating adolescent girls
The cost-effectiveness of vaccination in the United States against human papillomavirus (HPV), a sexually-transmitted virus that causes cervical cancer, will be optimized by achieving universal vaccine coverage in young adolescent girls, by targeting initial "catch-up" efforts to vaccinate women younger than 21 years of age, and by revising current screening policies, according to an analysis by Harvard School of Public Health (HSPH) researchers in the August 21, 2008 issue of
The New England Journal of Medicine.
Personalized immunotherapy to fight HIV/AIDS
For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.
Trapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.
New decision model seeks to avert flu vaccine mismatch of 2007-2008 season
To avoid producing vaccines that treat the wrong strains during flu season, the FDA should consider deferring some of its selections as well as other changes to the vaccine composition, according to a study by two decision analysts published in a journal of the Institute for Operations Research and the Management Sciences (INFORMS).
Giving an additional early vaccination may reduce measles outbreaks
Outbreaks of measles in developing countries may be reduced by vaccinating infants at 4.5 months of age as well as at the World Health Organization's recommended routine vaccination at 9 months, according to a study published on BMJ.com today.